By Samuel Indyk
Investing.com – Avacta Group (LON:AVCT) announced it has signed a non-exclusive distribution agreement with Calibre Scientific for its AffiDX SARS-CoV-2 antigen lateral flow test for professional use in the UK and European Economic Area (EEA).
Under the agreement, the test will be listed on Calibre’s website and be made available to be purchased by professional users.
“We are delighted that we have put in place this distribution agreement for the AffiDX SARS-CoV-2 antigen lateral flow test for professional use with Calibre,” said Avacta Group Chief Executive Officer Dr Alistair Smith.
“As a high quality, global distributor of diagnostics and life science products with excellent links to our target markets, we are confident Calibre is well placed to support our penetration of the professional end use market in the UK and EEA.”
After receiving approval in the UK and EU earlier this month, Avacta is also looking to offer its test to countries in other regions.
“Avacta will continue to focus on developing direct sales opportunities to major corporates and other large scale end users,” Smith said. “We are also in discussion with potential customers in territories outside the UK and EEA, including some of the APAC region, where the additional regulatory approvals required beyond CE marking are minimal.”
At 09:41BST, shares in Avacta Group were trading lower by 6.9% at 198.99 pence per share.